On 18 November, AZTherapies, a clinical-stage biopharmaceutical company developing novel therapies to change neurodegenerative diseases progression, announced the completion of its COGNITE Phase III clinical trial evaluating the safety, tolerability and efficacy of ALZT-OP1 for the treatment of early Alzheimer’s disease (AD). The last participant has completed all predefined assessments.
The COGNITE study is a 72-week global, randomised, double-blinded and placebo-controlled Phase III study designed to determine if ALZT-OP1 will slow down, arrests, or reverse cognitive and functional decline in people with early AD. The combination drug therapy ALZT-OP1 consists of the administration of two previously approved drugs for other indications that act on important mechanisms relevant to AD, with a new formulation to enable rapid pulmonary uptake and crossing of the blood-brain barrier.
More than 600 research participants from Australia, Europe and US were enrolled in the COGNITE trial. The company plans to begin data analysis soon and the top-line results are expected in the first quarter of 2021.
https://aztherapies.com/2020/11/18/aztherapies-completes-cognite-phase-3-trial/
